The Food and Drug Administration today issued Gilead Sciences an emergency use authorization for the investigational antiviral drug remdesivir to treat suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease.

FDA previously allowed for study of the drug under clinical trials, as well as expanded access use for individual patients and through a multi-patient expanded access program coordinated by Gilead.

The National Institutes of Health this week reported that a clinical trial provided preliminary indications that hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received a placebo.

Related News Articles

Headline
The Centers for Disease Control and Prevention yesterday broadened its masking guidance, enabling visitors of health care facilities to wear N95 masks.…
Headline
Pfizer yesterday asked the Food and Drug Administration to authorize a second booster dose of its COVID-19 vaccine for adults age 65 and older who…
Headline
Weekly COVID-19-associated hospitalization rates among U.S. infants and children under age 5 have declined since peaking Jan. 8, but peak rates during omicron…
Headline
The Food and Drug Administration recently authorized extending from six to nine months the shelf life for refrigerated Johnson & Johnson COVID-19…
Headline
The Transportation Security Administration will continue to require masks on public transportation through April 18 to protect against COVID-19, as the Centers…
Headline
In a study of 1,364 children aged 5-15, two doses of the Pfizer COVID-19 vaccine reduced the risk of omicron infection by 31% in those under 12 and 59% in…